Products & Programs PharmacyMedicare AdvantageFebruary 16, 2024

Anthem expands specialty pharmacy precertification list

Update: In the February 2024 edition of Provider News, we announced prior authorizations for the following drugs would be effective May 1, 2024. Please be advised that the prior authorization effective date for the drugs listed below will be June 1, 2024.

HCPCS or CPT® codes

Medicare Part B drugs

C9399

Adzynma (ADAMTS13, recombinant-krhn)

J3490, J3590, J9999

Aphexda (motixafortide)

C9160

Daxxify (daxibotulinumtoxinA-lanm)

J3490

Focinvez (fosaprepitant)

J3590

Omvoh (mirikizumab-mrkz)

J3490, J3590

Tofidence (tocilizumab-bavi)

Effective for dates of service on and after June 1, 2024, the specialty Medicare Part B drug listed in the table below will be included in our precertification review process.

Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

HCPCS or CPT codes

Medicare Part B drugs

J3490, J3590

Avzivi (bevacizumab-tnjn)

C9399, J3490, J3590

Loqtorzi (toripalimab-tpzi)

J3490

Rivfloza (nedosiran)

J3490, J3590

Ryzneuta (efbemalenograstim alfa-vuxw)

C9399, J3490

Wainua (eplontersen)

Notification of specialty pharmacy medical step therapy updates

Effective June 1, 2024, the following Part B medications from the current Clinical Criteria Guidelines will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below.

Clinical UM Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria.

Clinical UM Guidelines

Preferred drug(s)

Nonpreferred drug(s)

CC-0107

Avastin

Mvasi

Avzivi

Alymsys

Vegzelma

Zirabev

CC-0002

Neulasta

Neulasta OnPro

Udenyca

Ryzneuta

Fulphila

Fylnetra

Nyvepria

Rolvedon

Stimufend

Ziextenzo

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-051073-24-CPN50794

PUBLICATIONS: March 2024 Provider Newsletter